- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01813461
Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects
March 15, 2013 updated by: Astellas Pharma Global Development, Inc.
A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of Isavuconazole After a Single Oral Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled isavuconazole and the routes of excretion and the extent of metabolism of 14C-labeled prodrug BAL8557.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Subjects will be admitted to and stay in a clinical research unit for 23 days.
On Day 1, they will receive a single oral dose of BAL8557 and throughout the study period the excretion and metabolism of the study drug will be monitored.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Covance
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- The subject has a body weight of at least 45 kg and a body mass index of 18 to 32 kg/m2, inclusive.
- The subject's 12-lead electrocardiogram (ECG) is normal at Screening and Day -1; or, if abnormal, the abnormality is not clinically significant, including a QT interval corrected for heart rate using Fridericia's formula (QTcF) of 430 msec or less.
- The subject's clinical laboratory test results at Screening and Day 1 are within normal limits or not clinically significant.
- Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be within the normal range.
- The subject is surgically sterile or agrees to using a highly effective method of contraception to prevent pregnancy during the study and for at least 90 days after dosing on Day 1, and the subject agrees to not donate any sperm for at least 90 days after dosing on Day 1.
Exclusion Criteria:
- The subject has any clinically significant disease history or condition that precludes him from participating in the trial.
- The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome
- The subject has a history of bowel obstruction, swallowing disorder, severe gastrointestinal disorders, major gastrointestinal surgery, actively bleeding hemorrhoids, or gastric/duodenal ulcers.
- The subject has irregular bowel habits (< 1 bowel movement per day).
- The subject has had nuclear medicine procedures, computed tomography scans, or significant x-rays (other than dental) within the past 12 months, has had significant occupational radiation exposure, or participated in a radio-labeled study within the last 6 months or participated in more than one radio-labeled study within the last 12 months.
- The subject has a positive test for hepatitis B surface antigen or hepatitis C antibodies at Screening or is known to be positive for human immunodeficiency virus (HIV).
- The subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic admission on Day -1.
- The subject has received a vaccination within the last 30 days prior to study drug administration.
- The subject has a known or suspected allergy to any of the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods (as judged by the Investigator), or a history of severe anaphylactic reactions.
- The subject has used tobacco or nicotine containing products in the last 6 months.
- The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to Day -1, or over-the-counter medication within 1 week prior to Day -1, with the exception of occasional use of acetaminophen up to 2 g/day.
- The subject has participated in any interventional clinical study or has received any investigational agent within 30 days or 5 half-lives, whichever is longer, prior to the initiation of Screening.
- The subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on Day -1.
- The subject has taken part in strenuous exercise within 3 days prior to dosing on Day 1.
- The subject anticipates an inability to abstain from caffeine or alcohol use for 48 hours prior to clinic admission on Day -1 and throughout the duration of the study; or from grapefruit, grapefruit juice, star fruit, or Seville oranges or any products containing these items from 72 hours prior to clinic admission on Day -1 and throughout the duration of the study.
- The subject has a recent history (within the last 2 years) of drug or alcohol abuse or a positive drug screen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 14C-labeled prodrug isavuconazonium sulfate
single dose
|
oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radioactivity ratio blood/plasma
Time Frame: Day 1
|
Day 1
|
Radioactivity in whole blood and in plasma: Area under the concentration-time curve (AUC) from time of dosing to infinity (AUCinf)
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Radioactivity in whole blood and in plasma: AUC from time of dosing to the last quantifiable concentration (AUClast)
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Radioactivity in whole blood and in plasma: Maximum concentration (Cmax)
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Radioactivity in whole blood and in plasma: Time to Attain Cmax (tmax)
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Radioactivity in whole blood and in plasma: Apparent terminal elimination half-life (t1/2)
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Radioactivity in emesis (if applicable)
Time Frame: After study drug administration Days 1 up through 29
|
After study drug administration Days 1 up through 29
|
Excretion ratio and cumulative excretion of radioactivity in urine
Time Frame: Pre-dose and after dosing collection times: 0 to 6, 6 to 12, 12 to 24, and in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until discharge
|
Pre-dose and after dosing collection times: 0 to 6, 6 to 12, 12 to 24, and in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until discharge
|
Excretion ratio and cumulative excretion of radioactivity in feces
Time Frame: Pre-dose and after dosing in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until the day of discharge
|
Pre-dose and after dosing in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until the day of discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile of isavuconazole in plasma: AUCinf, AUClast, Cmax, tmax, Apparent body clearance after dosing (CL/F), Apparent volume of distribution (Vz/F), t1/2
Time Frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 216, 264, 312, 360, 408, 456, and 504 hours after radioactive dose. If subjects are not discharged on Day 22, blood will be collected at 576 and 648 hours after dosing
|
|
Pharmacokinetic Profile of isavuconazole in urine: Ae, Ae%, CLR
Time Frame: Pre-dose and 0 to 6, 6 to 12, 12 to 24, in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until day of discharge
|
Amount excreted (Ae), Percent of unchanged drug excreted into the urine (Ae%), Renal clearance (CLR)
|
Pre-dose and 0 to 6, 6 to 12, 12 to 24, in 24 hour intervals up to 504 hours after radioactive dose. If subjects are not discharged on Day 22, sample collection will continue in 24 hour intervals until day of discharge
|
Metabolic profile of isavuconazole and possible metabolites in plasma, urine, and feces
Time Frame: 8, 24,72, 144, and 312 hours after dosing. If subjects are not discharged on Day 22, samples will be taken at 504 hours after dosing
|
8, 24,72, 144, and 312 hours after dosing. If subjects are not discharged on Day 22, samples will be taken at 504 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
November 1, 2012
Study Completion (Actual)
November 1, 2012
Study Registration Dates
First Submitted
March 15, 2013
First Submitted That Met QC Criteria
March 15, 2013
First Posted (Estimate)
March 19, 2013
Study Record Updates
Last Update Posted (Estimate)
March 19, 2013
Last Update Submitted That Met QC Criteria
March 15, 2013
Last Verified
March 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9766-CL-0016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on 14C-labeled prodrug isavuconazonium sulfate
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of 14C-labeled Isavuconazonium SulfateUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHematological MalignancyUnited States
-
Spectrum Pharmaceuticals, IncTerminated
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707United Kingdom
-
Astellas Pharma Global Development, Inc.Completed
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of ASP1585United States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
Astellas Pharma Global Development, Inc.CompletedAdvanced Solid Tumors | Pharmacokinetics of 14C-labeled GilteritinibUnited States
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.CompletedHematologic Malignancy | Myeloproliferative DisorderUnited States